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ORIGINAL ARTICLE
Cardiac transplantation has been established as
an effective treatment for end-stage cardiac dis-
eases. However, despite the fact that advances in
immunosuppressive therapy and patient man-
agement during the past decade have improved
short-term survival following heart transplanta-
tion, mortality after the first year has remained
unchanged.1 Late graft loss in living patients 
is predominantly caused by chronic rejection.
Chronic rejection is a progressive, irreversible
disease that is characterized by deteriorating graft
function, interstitial fibrosis and occlusion of 
luminal structures such as arteries and epithelial-
lined conduits.2 Chronic rejection of cardiac allo-
grafts is manifested by the development of cardiac
allograft vasculopathy (CAV) and interstitial 
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Background/Purpose: Chronic rejection limits the long-term success of cardiac transplantation and the
underlying cause of the disease is unknown. Connective tissue growth factor (CTGF) is considered as a mito-
genic and chemotactic factor for fibroblasts, and is associated with cell proliferation and collagen synthesis.
We evaluated the expression of CTGF in a rat model of heart allograft chronic rejection.
Methods: Intra-abdominal heterotopic heart transplantation was performed from 20 Wistar rats to 20
Sprague–Dawley (SD) rats that received cyclosporine, mycophenolate mofetil and methylprednisolone as
immunosuppression. Ten heart allografts were explanted at 2 and 8 weeks postoperatively for analysis of
morphologic changes. The hearts from 10 normal Wistar rats served as a control group. Coronary artery
density, luminal loss of myocardial coronary arteries, and myocardial fibrosis were measured. The expression
of CTGF was studied by immunohistochemistry. Correlation between CTGF expression and development
of cardiac allograft vasculopathy (CAV) or fibrosis was studied.
Results: Allografts harvested at 8 weeks postoperatively showed more coronary intimal proliferation, 
fibrosis and CTGF expression compared with the 2-week allografts (p < 0.05) and the controls (p < 0.01),
but the coronary artery density was lower than in the control group (p < 0.05). However, the control group
showed negligible CTGF expression. There were strong negative correlations between the gray value of
CTGF protein expression and cardiac fibrosis and coronary intimal occlusion (r = –0.734, –0.713; p < 0.01),
which demonstrated that CTGF protein expression was positively correlated with cardiac fibrosis and
coronary intimal occlusion.
Conclusion: CTGF is expressed in cardiomyocytes in CAV. Increased expression of CTGF in cardiac allografts
is associated with development of CAV and fibrosis formation. [J Formos Med Assoc 2009;108(3):240–246]
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fibrosis.3–5 The classic vascular lesions of CAV are
characterized by diffuse, concentric intimal thick-
ening composed primarily of modified smooth
muscle cells (SMCs).3 CAV may affect vessels
along their entire length, and intimal thickening
may thus be seen in large and small arteries. It is
not only limited to coronary arteries but may be
present in coronary veins in explanted human
hearts.6 Despite intense investigation, the etiology
and associated pathology of chronic rejection are
still not clear. Results from many different labo-
ratories have identified several major cytokines
that may contribute to this process, and the most
important of these is transforming growth factor-β
(TGF-β).7,8 TGF-β not only has a fibrogenic 
effect, but also has several major physiologic roles,
including suppression of the immune system,
that are viewed as beneficial in inflammation,
transplantation and epithelial proliferation.8,9
As a result, it is largely assumed that, from clini-
cal and pharmaceutical standpoints, long-term
inhibition of TGF-β may be a less suitable strat-
egy to prevent chronic rejection after heart 
transplantation.
Connective tissue growth factor (CTGF) is a
recently recognized downstream effector of TGF-β.
CTGF is a 38-kDa, heparin-binding, cysteine-rich
protein that can induce cell proliferation, colla-
gen synthesis and chemotaxis in a variety of cells
including endothelial cells, SMCs and fibro-
blasts.10,11 The CTGF promoter contains Smad
binding elements and a unique TGF-β response
element,12 CTGF mediates many of the fibrogenic
activities of TGF-β and plays a more specific role
as a fibrogenic cytokine,13–15 but CTGF alone is
not involved in the immunomodulatory effects of
TGF-β.15 Thus CTGF might be used as a potential
target for preventing chronic rejection, while spar-
ing the anti-inflammatory and anti-proliferative
activities of TGF-β. More recently, CTGF has 
been found to be overexpressed in chronic allo-
graft nephropathy.16,17 However, few studies had
focused on its role during the process of heart 
allograft fibrosis and CAV.
Hence, to further explore the relationship be-
tween CTGF and chronic heart allograft injury, we
tested CTGF expression by immunohistochemi-
cal staining, using a rat heart transplant model.
Methods
Animals
Twenty inbred male SD rats and 30 inbred male
Wistar rats were purchased from the laboratory
of the Second Xiangya Hospital, Changsha,
Hunan, China. The rats were 6–8 weeks of age
and weighed 250–300 g and were housed under
specific pathogen-free conditions in the Unit for
Laboratory Animal Medicine at the Second
Xiangya Hospital. The animals were fed with reg-
ular rat food and tap water ad libitum. The Wistar
rats served as heart graft donors and the SD rats
as the recipients. The study was approved by 
the institutional ethics committee on animal 
research.
Heterotopic cardiac transplantation
The rat model of heterotopic cardiac transplanta-
tion was performed according to the method of
Ono and Lindsey, with some modifications.18
Briefly, rats were anesthetized with intraperitoneal
injection of 5% chloral hydrate. The recipient ab-
domen was opened before the donor heart was
explanted, in order to reduce the ischemic time.
Immediately after explantation, the ascending
aorta and pulmonary artery of the donor heart
were anastomosed to the infrarenal abdominal
aorta and inferior vena cava of the recipient in an
end-to-side fashion. The donor heart was per-
fused with recipient rat’s blood and resumed
contraction. Total procedure time averaged 58
minutes. Graft survival was monitored by daily
abdominal palpation. Penicillin was administered
at a dose of 10 × 104 U by intramuscular injection
to the recipient immediately after transplantation
and lasted for 3 days. The immunosuppressive
regimen consisted of intramuscular cyclosporine
(10 mg/kg/day), and mycophenolate mofetil
(40 mg/kg/day) and methylprednisolone (3 mg/
kg/day) by gavage from the second day after
transplantation until specimens were harvested.
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The control group received the same immuno-
suppressive regimen as the allograft recipients.
Grouping and acquisition of samples
Ten transplants were harvested at 2 and 8 weeks
postoperatively. Hearts from 10 normal Wistar
rats served as a control group. The left ventricular
wall tissues taken from the transplants immedi-
ately after sacrifice were fixed in 10% buffered for-
malin solution, routinely embedded in paraffin,
and then serially sectioned at a thickness of 4 μm.
Cardiac histology
The paraffin sections were stained with hema-
toxylin and eosin (HE) for examination of patho-
logic morphology and stained with Van Gieson
stain to delineate the internal elastic lamina. The
mean total number of coronary artery vessels in
five randomly chosen fields of view (50× magni-
fication) was defined as myocardial coronary ar-
tery density. The Northing Medical Image Analysis
Management System, Mias System 4.1 (Beijing
University of Aeronautics & Astronautics, China),
was used to measure the area surrounded by the
internal elastic lamina and vessel lumen. Each
artery was assessed for percentage of intimal pro-
liferation (percentage of luminal occlusion), de-
fined as the intimal area divided by the overall
area inside the elastic lamina (intimal area plus
luminal area).19 Graft interstitial fibrosis was es-
timated from sections stained with HE and scored
semiquantitatively: 0, no fibrosis; 1, mild fibrosis;
2, moderate fibrosis; and 3, intense interstitial fi-
brosis.20 All analyses were performed in a blinded
manner by two independent observers.
Immunohistology
The streptavidin–biotin–peroxidase complex
(SABC, SA1052) immunohistochemistry kit was
purchased from Boster Biological Technology Co.,
Ltd. (Wuhan, China). Formalin-fixed, paraffin-
embedded sections were deparaffinized and re-
hydrated with distilled water. Endogenous
peroxidase was blocked using blocking buffer
(3% H2O2) and antigen retrieval was performed
in a pressure sterilizer. After the primary rabbit
anti-CTGF antibody (diluted 1:100) was added
and set for 1 hour in a wetting case at 37°C, the
slides were washed with phosphate-buffered saline
(PBS), and incubated with biotinylated goat anti-
rabbit secondary antibody for 15 minutes in a wet-
ting case at 37°C. Then, the slides were incubated
with SABC for 20 minutes in a 37°C water bath.
After washing with PBS, the slides were incubated
with 3,3’-diaminobenzidine. Then, the slides were
counterstained with hematoxylin before mounting
and evaluation. Negative controls were performed
using PBS instead of CTGF antibody. Semiquanti-
tative scoring of CTGF expression was analyzed on
a digitally acquired image by the Mias System 4.1.
From the image, the expression of CTGF was ob-
tained by determining the average gray scale of
masculine grana. The smaller the gray scale value,
the deeper the masculine coloration, which sig-
nified a larger amount of CTGF protein expression.
For every slide, eight integral and non-overlapping
visual fields were chosen at random to obtain the
semiquantitative scores. The mean score of the
eight fields gray scale was considered to represent
the extent of CTGF expression.
Statistical analysis
All data are shown as mean ± standard error of
the mean. Analyses were performed using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA) for
Windows. Comparison of the percentage of inti-
mal occlusion, cardiac vessel density and CTGF
expression between the three groups was per-
formed using ANOVA. Differences in myocardial
fibrosis were determined using the Kruskal–Wallis
test. Tests of association between levels of CTGF
expression and myocardial fibrosis or high-grade
CAV (> 50% occlusion) were performed using
Spearman correlation tests. A value of p < 0.05
was considered statistically significant.
Results
Histology examination
None of the biopsies in the control group demon-
strated evidence of inflammatory or abnormal 
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fibrosis, with uniform staining of cardiac muscle,
no granulocyte infiltration, and thin vessel walls
(Figures 1A, D and G). However, with the charac-
teristic presence of concentric intimal prolifera-
tion and inflammatory infiltration of the arterial
intima, CAV was seen in the 2-week group (Figures
1B, E and H), and became even more severe in
the 8-week group, with the vessel in a “triangular
shape” (Figures 1C, F and I). Interstitial fibrosis
was more obvious in the 8-week group; the colla-
gen deposition was mainly in the interstitium,
around the blood vessels and cardiac myocyte
with fiber derangement. However, there were less
inflammatory infiltration and lower coronary ar-
terial density compared with the 2-week group.
Cardiomyocyte apoptosis was seen in the 8-week
group; with the reliquus cardiac myocyte, islands
of myocardium are formed.
Comparison of the indexes among 
different groups
The allograft hearts in the 8-week group showed
the lowest coronary arterial density (0.58 ± 0.22)
and comparisons between the three groups
showed significant differences between the con-
trol and 8-week group (p < 0.01) (Table). We iden-
tified increased fibrosis formation in the 2-week
group (1.15 ± 0.36), but the highest fibrosis forma-
tion was in the 8-week group (2.75 ± 0.45). Statis-
tical comparison showed significant differences
A B C
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Figure 1. Light microscopy of rat heart grafts over time course of transplantation (original magnification, 200×). Sections
were stained with hematoxylin and eosin (A–C) or Van Gieson stain (D–I). Panels A, D and G are the control group.
Panels B, E and H are the 2-week group. Panels C, F and I are the 8-week group.
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between the transplantation groups (p < 0.05) and
between the transplantation groups and the con-
trol group (p < 0.05, p < 0.01). Similar findings
were observed when we compared the percent-
age of intimal occlusion, with the 8-week group
having the greatest degree of intimal occlusion
compared with the other two groups (p < 0.01).
Increased expression of CTGF is associated
with allograft fibrosis and CAV formation
Hearts obtained from the control group showed
negligible amounts or an absence of CTGF ex-
pression (Figure 2A). In contrast, immunoreac-
tivity for CTGF localized to cardiomyocytes,
thickened coronary artery wall and the intersti-
tium was detectable in the 2-week group (Figure
2B), but was less obvious compared with that in
the 8-week group (Figure 2C). Also, the mean
gray scale value was highest in the control group,
which signified a smaller amount of CTGF pro-
tein compared with that in the transplantation
group (p < 0.01) (Figure 3). There was also a sig-
nificant difference concerning CTGF expression
between the transplantation groups (p < 0.01)
(Figure 3). We subsequently evaluated whether
myocardial fibrosis and high-grade CAV were 
associated with the expression of CTGF. To deter-
mine a possible association, we grouped all rat
hearts, irrespective of study group, and found a
significant negative association between myocar-
dial fibrosis and the mean gray scale value
(r = –0.734, p < 0.01), which signified a strong
positive correlation between CTGF protein ex-
pression and myocardial fibrosis. The same posi-
tive correlation was found between CTGF protein
A B C
Figure 2. Immunostaining for CTGF in heart allografts after transplantation (original magnification, 400×). Sections were
stained with Van Gieson stain. (A) The control heart showed an absence of detectable protein. (B) In the 2-week allograft,
the expression was readily detectable. (C) In the 8-week allograft, the expression was much more obvious, and was 
predominantly in the cardiomyocytes, incrassated coronary vessel wall and myocardial interstitium.
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Figure 3. Comparison of CTGF protein expression (mean
gray scale value) among groups. Analyzed by ANOVA.
*p < 0.01 vs. control; †p < 0.01 vs. 2-week group.
Table. Comparison of indexes of rat hearts in the different study groups. Analyzed by ANOVA or Kruskall–
Wallis test (fibrosis grade)
n Coronary vessel density Fibrosis grade (0–3) Intimal occlusion (%)
Control group 10 3.57 ± 0.54 0.00 ± 0.01 0.07 ± 0.03
2-wk group 10 3.02 ± 0.43 1.15 ± 0.36* 27.58 ± 11.14*
8-wk group 10 0.58 ± 0.22* 2.75 ± 0.45*† 72.29 ± 20.57*†
*p < 0.05 vs. control group; †p < 0.05 vs. 2-week group.
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expression and percentage of luminal occlusion,
which was an indicator of CAV formation.
Discussion
Here, we showed a time-dependent increase in
CTGF expression in a rat model of heterotopic
heart transplantation. Additionally, we demon-
strated a strong positive association between
CTGF expression and CAV formation. These re-
sults indicate that CTGF plays an active role in 
allograft fibrosis formation and CAV pathology.
CAV may affect not only the coronary arteries,
but also coronary veins of explanted human
hearts.6 We observed that the coronary vessel
density was greatly decreased in the 8-week com-
pared with the 2-week or the control group, and
a diffuse concentric intimal thickening, which
meant that this model was sufficient for our
study. We also found intimal proliferation in the
2-week group, with abundant lymphocyte and
macrophage infiltration. This suggested that car-
diac artery vasculopathy began to form during the
cellular rejection phase. As acute moderate/severe
cellular rejection has a cumulative impact on car-
diac artery vasculopathy onset,21 we should treat
cellular rejection more actively to abate chronic
rejection.
We observed overexpression of CTGF in heart
allografts in a time-dependent manner and a
positive correlation between CTGF expression
and fibrosis. CTGF was predominantly expressed
in the cardiomyocytes, incrassated coronary vessel
wall and myocardial interstitium in heart allo-
grafts. Koitabashi et al found that cardiomyocytes
can secrete CTGF and thus promote cardiac fibro-
blast proliferation, and that this process regulates
production of collagen in hearts with diastolic
failure.22 In heart allografts, we found that colla-
gen was deposited mainly in the interstitium,
around the blood vessels and cardiac myocyte
with fiber derangement. The results showed that
the expression level of CTGF was elevated in
heart grafts with more severe fibrotic lesions and
chronic rejection. CTGF-mediated fibrosis does
not appear to be heart allograft specific, as in
kidney allografts that overexpress CTGF, which
can induce epithelial–mesenchymal transforma-
tion to myofibroblasts (α-smooth muscle actin
positive) and thus lead to allograft fibrogenesis.17
In our 2-week allografts, there was increased CTGF
and fibrosis formation, and because myocardial
fibrosis is considered as a marker for non-
immune-mediated graft injury independently 
associated with an increased incidence of CAV in
acute rejection,23 this suggests that we should treat
cellular rejection more actively.
However, there was no detectable expression
of CTGF in normal control rat hearts, which 
contrasts with the observations of Chen et al,
who reported CTGF expression in cultured car-
diomyocytes and fibroblasts.14 This outcome
might be explained by the difference in the spec-
imens: we used fresh rat ventricular walls, while
Chen et al used cultured ventricular cells and 
fibroblasts.
There are several limitations to the present
study. As a result of the non-availability of com-
mercial reagents for ELISA detection of CTGF, we
did not detect CTGF expression in the blood,
which hindered the consideration of CTGF as a
biomarker of chronic rejection. The limited
number of rats used and the lack of a study on
patients limit the power of the study. We also did
not test the role of CTGF on myocardial vessel
SMCs in vitro, thus we did not demonstrate a
functional role of CTGF in CAV formation in this
model. However, the functional role of CTGF has
been made clear by neutralization or downmod-
ulation of its activity in vitro using siRNA24 or by
antisense oligonucleotides in an ex vivo setting.25
Further study should concentrate on this to
make it clinically practical.
In summary, we demonstrated that CTGF was
expressed in cardiomyocytes during CAV and
overexpression of CTGF correlated with allograft
fibrosis and CAV in a rat model of cardiac allo-
graft chronic rejection. Further study into the
functional role of CTGF in the development of
CAV, and its potential as a surrogate marker of
graft rejection status and outcome is required.
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